Celecoxib
Other name
DB00482
International/Other brands
Act Celecoxib
Groups
Approved
Structure
Prescription products
| Name | Dosage | Strength | Route | Labeller |
|---|---|---|---|---|
| Accel-celecoxib | Capsule | 200 mg | Oral | Accel Pharma Inc |
| Accel-celecoxib | Capsule | 100 mg | Oral | Accel Pharma Inc |
| Act Celecoxib | Capsule | 200 mg | Oral | Actavis Pharma Company |
| Act Celecoxib | Capsule | 100 mg | Oral | Actavis Pharma Company |
| Ag-celecoxib | Capsule | 200 mg | Oral | Angita Pharma Inc. |
| Ag-celecoxib | Capsule | 100 mg | Oral | Angita Pharma Inc. |
| Auro-celecoxib | Capsule | 200 mg | Oral | Auro Pharma Inc |
| Auro-celecoxib | Capsule | 100 mg | Oral | Auro Pharma Inc |
| Bio-celecoxib | Capsule | 200 mg | Oral | Biomed Pharma |
| Bio-celecoxib | Capsule | 100 mg | Oral | Biomed Pharma |
Target
-
Description
Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms, and to reduce numbers of colon and rectum polyps in patients with familial adenomatous polyposis. It is marketed by Pfizer under the brand name Celebrex. In some countries, it is branded Celebra. Celecoxib is available by prescription in capsule form.
Indications
For relief and management of osteoarthritis (OA), rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA), ankylosing spondylitis, acute pain, primary dysmenorrhea and oral adjunct to usual care for patients with familial adenomatous polyposis
Other indications
-
Mechaism of action
-
Absorption
Well absorbed in the gastrointestinal tract. When a single dose of 200 mg is given to healthy subjects, peak plasma levels occur 3 hours after an oral dose. The peak plasma level is 705 ng/mL. Absolute bioavailability studies have not been conducted. When multiple doses are given, steady-state is reached on or before Day 5. When taken with a high fat meal, peak plasma levels are delayed for about 1 to 2 hours with an increase in total absorption (AUC) of 10% to 20%.
Metabolism
Hepatic. Celecoxib metabolism is primarily mediated via cytochrome P450 2C9. Three metabolites, a primary alcohol, the corresponding carboxylic acid and its glucuronide conjugate, have been identified in human plasma. CYP3A4 is also involved in the hydroxylation of celecoxib but to a lesser extent. These metabolites are inactive as COX-1 or COX-2 inhibitors.
Toxicity
Symptoms of overdose include breathing difficulties, coma, drowsiness, gastrointestinal bleeding, high blood pressure, kidney failure, nausea, sluggishness, stomach pain, and vomiting.